Day: November 3, 2022

On April 9, 2014, Liu, Changdou published a patent.Computed Properties of 23256-42-0 The title of the patent was Compound colinflosaxin soluble powder for preventing and treating poultry colibacillosis. And the patent contained the following:

The invention discloses a compound colinflosaxin soluble powder for preventing and treating poultry colibacillosis, wherein the solubility powder is made of following components by weight percent: colinflosaxin 4-10%, florfenicol sodium succinate 5-10%, neomycin sulfate 3-10%, trimethoprim lactate 3-8%, and pharmaceutically acceptable adjuvants in balance. The invention importantly considers drug resistance properties of Escherichia coli, will not miss any one pathogenic microorganism, and comprehensively considers the reasons of harm to body, has broad spectrum, is effective to Escherichia coli, has strong antibacterial activity, adopts novel antibacterial drugs, such as colinflosaxin, florfenicol sodium succinate, by combining both of them for use, its antibacterial activity compared with conventional antibacterial drugs is greatly increased, and can effectively control secondary infection. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Computed Properties of 23256-42-0

The Article related to colinflosaxin powder poultry colibacillosis, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 20, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Compound sulfaquinoxaline sodium composition for treating coccidiosis of young rabbits. And the patent contained the following:

The title composition contains toltrazuril 0.5-1, sulfaquinoxaline sodium 4-6, trimethoprim lactate 0.8-1.2, sodium citrate 15-25, sodium CM-cellulose 1.5-2.5, sodium sulfite 0.2-0.5, EDTA-2Na 0.2-0.5 weight part, and distilled water. The preparation method of the composition comprises: taking all materials, grinding, screening via 80 mesh sieve; taking sodium sulfite and EDTA-2Na, dissolving in distilled water sequentially, stirring uniformly, adding sodium citrate, mixing for 5-10min; adding toltrazuril, sulfaquinoxaline sodium and trimethoprim lactate, mixing for 5-10min, adding sodium CM-cellulose, stirring uniformly, and filtering. The composition has simple preparation method, and obvious curative effect on coccidiosis of young rabbits. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to sulfaquinoxaline sodium composition coccidiosis, Pharmaceuticals: Formulation and Compounding and other aspects.Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 1982, Takagishi, Yasushi; Ohsuga, Kiichiro; Ohama, Sadao published a patent.Related Products of 23256-42-0 The title of the patent was Suppositories containing sulfamethoxazole and trimethoprim. And the patent contained the following:

A pharmaceutical or veterinary composition for coelomic administration, especially a suppository, contains sulfamethoxazole (I) [723-46-6] and trimethoprim (II) [738-70-5] (1:1-10:1) or their salts and a small amount of a phospholipid to prevent solidification during mixing the above ingredients and to avoid the delayed disintegration. An organic acid may be added to increase the absorption of II. Thus, a suppository containing I 20, II 4, soybean lecithin 2, and Witepsol 74 parts had a disintegration time of 13 min after storage at room temperature for 3 mo, whereas the control without the lecithin did not decompose even after 60 min. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to sulfamethoxazole trimethoprim suppository lecithin, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 11, 2006, Wang, Lianmin; Zhang, Xinglong; Hua, Yunfang published a patent.Category: pyrimidines The title of the patent was Manufacture of veterinary amikacin sulfate compound injection containing trimethoprim. And the patent contained the following:

The title injection is manufactured by: (1) dissolving trimethoprim lactate into injection water, and adding propanediol, (2) dissolving sodium metabisulfite into injection water, (3) dissolving amikacin sulfate in injection water, and (4) mixing solutions obtained from step 1, 2, and 3, adjusting pH to 4.0-5.0, prefiltering, microfiltering, and sterilizing to obtain the final product. This injection can be used to synthesize abnormal proteins from bacteria to inhibit proteins from releasing, and enlarge cell membrane permeability of bacteria to inhibit proliferation of bacteria. This injection has reinforced antibacterial effect through synergistic effect of trimethoprim and amikacin sulfate. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to veterinary amikacin sulfate injection trimethoprim, Pharmaceuticals: Formulation and Compounding and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about pharmaceutical powders, synergism.Category: pyrimidines The title of the patent was Florfenicol soluble powder powder medicine. And the patent contained the following:

The present invention discloses a soluble powder medicine of florfenicol, which relates to the tech. field of veterinary medicine. The composition of florfenicol soluble powder powder medicine is: florfenicol, anhydrous citric acid, trimethoprim lactate and anhydrous glucose. The florfenicol soluble powder powder medicine of the present invention can be quickly dissolved in water to achieve the purpose of being soluble, and has the advantages of convenient administration and rapid onset of action. The combined use of florfenicol and a synergist enhances the therapeutic effect of the overall powder, improve the efficacy. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to florfenicol citric acid trimethoprim lactate powder, Pharmaceuticals: Formulation and Compounding and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 20, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Electric Literature of 23256-42-0 The title of the patent was Method for preparation of composite gentamicin sulphate composition for treating poultry diarrhea. And the patent contained the following:

Title composition is prepared from gentamicin sulfate 5-10, ciprofloxacin hydrochloride 10-15, berberine hydrochloride 10-20, trimethoprim lactate 5-9, and anhydrous glucose 46-70 weight parts. The preparation process includes uniformly mixing gentamicin sulfate, ciprofloxacin hydrochloride and anhydrous glucose (15-25 weight parts) for 5-10 min, uniformly mixing berberine hydrochloride, trimethoprim lactate and anhydrous glucose (15-29 weight parts) for 5-10 min, merging the two mixture, and mixing with residual anhydrous glucose for 10-15 min to obtain the composite gentamicin sulfate composition The composite gentamicin sulfate composition has advantages of simple preparation process and good therapeutic effect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Electric Literature of 23256-42-0

The Article related to gentamicin sulfate poultry diarrhea veterinary drug, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 17, 2010, Xu, Kefu published a patent.Application of 23256-42-0 The title of the patent was Compounded amoxicillin soluble powder for treating duck serositis and preparation method thereof. And the patent contained the following:

The compounded amoxicillin soluble powder is prepared from (by weight%) amoxicillin 2-20, sulfamonomethoxine sodium 2-20, trimethoprim lactate 0.4-4, diclofenac sodium 2-10, anhydrous sodium carbonate 1-8, and anhydrous glucose as balance. The preparation method comprises grinding each material, and then mixing for 1 h. By cooperative effect between amoxicillin and sulfamonomethoxine sodium, the drug resistance of Riemerella anatipestifer is greatly reduced, the pathogen-resisting ability is increased, and secondary infection can be also inhibited. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to amoxicillin soluble powder duck serositis veterinary, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 10, 2015, Wang, Yuwan; Dai, Xiaoxi; Pan, Zhende; Ren, Yanan; Li, Lei; Li, Ying; Weng, Zhifei; Shen, Li published a patent.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Preparation method of emulsifiable oleaginous injection containing hydrophilic medicine. And the patent contained the following:

The title emulsifiable oleaginous injection containing hydrophilic medicine is composed of hydrophilic medicine (such as valnemulin hydrochloride, tiamulin fumarate, etc.) 80-200g, poloxamer 188 20-60g, soybean phospholipids 1-5g and injection soybean oil or soybean oil/ethyl oleate to 1L. The preparation method of the emulsifiable oleaginous injection includes sterilizing injection soybean oil by heating, cooling, adding other materials and sand milling. Emulsification of emulsifiable oleaginous injection containing hydrophilic medicine occurs, when the emulsifiable oleaginous injection contacts to water, forming a emulsion or emulsion/oil system, thus reducing the release rate of drug. The emulsifiable oleaginous injection has large drug load, good biocompatibility, good stability and easy preparation method. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to hydrophilic medicine emulsifiable oleaginous injection, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 12, 1976, Alvan, George E.; Holstius, Elvin A. published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Solution containing trimethoprim, sulfacetamide, and polymyxin. And the patent contained the following:

Ophthalmic solutions for the treatment of microbial (especially bacterial) infections containing sulfacetamide (I) [144-80-9], a trimethoprim salt, and polymyxin salt were reported. E.g., an ophthalmic solution contains I 0.50, trimethoprim hemisulfate [56585-33-2] 0.123 g, polymyxin B sulfate [1405-20-5], 1,200,000 units, thimerosal 0.001, NaCl 0.83 g, and water for injection to 100.00 ml. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to trimethoprim sulfacetamide polymyxin ophthalmic solution, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 2010, Dong, Wei; Li, Xiaowen; Sun, Zhiliang published a patent.HPLC of Formula: 23256-42-0 The title of the patent was Long-acting antibacterial medicinal water-in-oil emulsion and its preparation method. And the patent contained the following:

The title emulsion is composed of water phase, oil phase, emulsifying agents and stabilizers. The oil phase is white oil 7# or 15#. The water-phase emulsifying agent is tween 80 and the oil-phase emulsifying agent is span 80. The emulsion is prepared by adding water-phase stabilizer into water at 40-45°, cooling to room temperature, dissolving antibacterial drug, adding tween 80, stirring to obtain water phase, adding 65-130° white oil 7# or 15# into oil-phase stabilizer, stirring, cooling to 50-60°, dissolving span 80, stirring to obtain oil phase, mixing water phase with oil phase, emulsifying and sterilizing. The antibacterial drug can be slowly released from the emulsion. The emulsion may be used as veterinary medicine for preventing and treating animal diseases in breeding field. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).HPLC of Formula: 23256-42-0

The Article related to veterinary antibacterial drug sustained release emulsion, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia